| Dr Ashish Nikhil Doshi, MD | |
|
111 Michigan Ave Nw, Washington, DC 20010-2916 | |
| (919) 672-3793 | |
| Not Available |
| Full Name | Dr Ashish Nikhil Doshi |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 13 Years |
| Location | 111 Michigan Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053608315 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
Mylan N.V. today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda Pharms' Felbatol Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product.
A $9.6 million grant from the National Institutes of Health has been awarded to the University of Illinois at Chicago to study access to care and health disparities among underserved and minority women with breast cancer in Chicago.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced on June 15, 2010 that its 51% owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility.
A researcher at the University of California, San Diego (UCSD) School of Medicine suggests that psychiatrists may need to approach the treatment of psychiatric patients from a new direction - by understanding that such individuals' behavior and decision-making are based on an attempt to reach an inner equilibrium.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 1 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Mylan N.V. today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda Pharms' Felbatol Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product.
A $9.6 million grant from the National Institutes of Health has been awarded to the University of Illinois at Chicago to study access to care and health disparities among underserved and minority women with breast cancer in Chicago.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced on June 15, 2010 that its 51% owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility.
A researcher at the University of California, San Diego (UCSD) School of Medicine suggests that psychiatrists may need to approach the treatment of psychiatric patients from a new direction - by understanding that such individuals' behavior and decision-making are based on an attempt to reach an inner equilibrium.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ashish Nikhil Doshi, MD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-6423 | Dr Ashish Nikhil Doshi, MD 111 Michigan Ave Nw, Washington, DC 20010-2916 Ph: (919) 672-3793 |
News Archive
Mylan N.V. today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda Pharms' Felbatol Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product.
A $9.6 million grant from the National Institutes of Health has been awarded to the University of Illinois at Chicago to study access to care and health disparities among underserved and minority women with breast cancer in Chicago.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced on June 15, 2010 that its 51% owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility.
A researcher at the University of California, San Diego (UCSD) School of Medicine suggests that psychiatrists may need to approach the treatment of psychiatric patients from a new direction - by understanding that such individuals' behavior and decision-making are based on an attempt to reach an inner equilibrium.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 1 days ago
Dr. Talita Michelle Jordan, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-5000 | |
Yue-hin Loke, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 111 Michigan Ave Nw, W3.5, 600, Washington, DC 20010 Phone: 202-476-3670 | |
Elshadey Yayehyerade Bekele, Pediatrics Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 301-565-4279 | |
Jia Liu, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-5000 | |
Dr. Charles John Billington Jr., MDPHD Pediatrics Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, W3.5, 600, Washington, DC 20010 Phone: 202-476-3670 Fax: 202-476-4741 | |
Dr. Joy Marie Morgan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-5000 | |
Nicole V Lang, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1145 19th St Nw, Ste 708, Washington, DC 20036 Phone: 202-955-5625 Fax: 202-955-5626 |